A High-Density Lipoprotein Raising Drug That Has a Lower Discontinuation Rate Than That of Extended Release Niaspan Would Earn a 20 Percent Patient Share in the Dyslipidemia Drug Market

Wednesday, July 30, 2008 General News
Email Print This Page Comment
Font : A-A+

WALTHAM, Mass., July 29 Decision Resources, one of theworld's leading research and advisory firms focusing on pharmaceutical andhealthcare issues, finds that a drug that raises high-density lipoproteincholesterol and has a lower discontinuation rate than that of Abbott's NiaspanER (extended release) would earn a 20 percent patient share in the treatmentof dyslipidemia, according to surveyed endocrinologists.

The new report entitled Dyslipidemia: Blockbuster Potential for Agentsthat Target HDL finds that although lowering low-density lipoproteincholesterol levels is at the forefront of treating dyslipidemia, researchersare now aware that increasing high-density lipoprotein cholesterol levels mayalso help reduce cardiovascular risk.

The report also finds that surveyed endocrinologists do not expect anytherapy under development to displace AstraZeneca's Crestor as the DecisionResources' proprietary clinical gold standard for dyslipidemia through 2016.Although some therapies in development hold promise, most have efficacy,safety and tolerability, and/or delivery features that merit inferior scorescompared with Crestor.

"For the majority of end points, endocrinologists we surveyed perceive thestatin class to be very similar," said Graeme Green, Ph.D., analyst atDecision Resources. "However Crestor positively differentiates itself in itsgreater ability to improve low- and high-density lipoprotein cholesterollevels."

About the Report

Dyslipidemia: Blockbuster Potential for Agents that Target HDL is aDecisionBase 2008 report from Decision Resources. DecisionBase 2008 combinesmarket forecasts with clinical and commercial end points to assess marketshare projections in 35 indications. These outputs are driven by quantitativeand qualitative primary research. DecisionBase 2008 provides detailed marketshare, patient share, and price-per-day projections for emerging drugs indevelopment. The market share projections are based on prescriber surveys thatcompare physicians' expectations of a potential target product profile with anemerging product profile of the leading drugs in development.

The report can be purchased by contacting Decision Resources. Members ofthe media may request an interview with an analyst.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in marketresearch publications, advisory services and consulting designed to helpclients shape strategy, allocate resources and master their chosen markets.Decision Resources is a Decision Resources, Inc. company.

All company, brand or product names contained in this document may betrademarks or registered trademarks of their respective holders.For more information, contact: Elizabeth Marshall Decision Resources 781-296-2563 emarshall@dresources.com

SOURCE Decision Resources


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook